Citigroup’s Syndax Pharmaceuticals SNDX Stock Holding History

Citigroup’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Buy	60,000 +30,000	+100%	+$624K	﹤0.01%	3257
2026 Q1	$701K	Hold	30,000	–	–	﹤0.01%	3347
2025 Q4	$630K	Buy	+30,000	New	+$523K	﹤0.01%	3445
2025 Q3	–	Sell	-58,300	Closed	-$546K	–	6304
2025 Q2	$546K	Hold	58,300	–	–	﹤0.01%	3574
2025 Q1	$716K	Buy	+58,300	New	+$822K	﹤0.01%	3476
2023 Q2	–	Sell	-29,900	Closed	-$631K	–	5715
2023 Q1	$631K	Buy	+29,900	New	+$744K	﹤0.01%	2943

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Citigroup's SNDX Position: Q2 2026 in Review

Citigroup increased its Syndax Pharmaceuticals (SNDX) stake by 863% in Q2 2026, buying an estimated $3.65M and bringing the position to 195,703 shares worth $4.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2283.

Citigroup first reported a position in SNDX in Q2 2016 and has held it in 40 quarters since. The position peaked at $12.8M in Q3 2022. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Citigroup held 195,703 shares of Syndax Pharmaceuticals worth $4.28M as of Q2 2026.
Citigroup bought 175,371 Syndax Pharmaceuticals shares in Q2 2026, an estimated $3.65M.
Syndax Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2283 holding.
Citigroup first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 40 quarters since.
Citigroup's Syndax Pharmaceuticals position peaked at $12.8M in Q3 2022.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.